Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments

Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at other companies

AbbVie logo
AbbVieABBV
——

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%
Enterprise value$1.88B+100.0%
P/S23.3×-26.8×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments?
AbCellera Biologics Inc. (ABCL) reported equity securities without readily determinable fair value - cumulative downward adjustments of $32.5M in Q1 2026.
How has AbCellera Biologics Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?
AbCellera Biologics Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments increased by 0.6% year-over-year, from $32.3M to $32.5M.
What is the long-term trend for AbCellera Biologics Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments?
Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments has grown at a 20.7% compound annual growth rate (CAGR), from $18.5M to $32.5M.